Eisai And Biogen To Discontinue Phase III Clinical Studies Of BACE Inhibitor Elenbecestat In Early Alzheimer’s Disease Read more
Vertex Announces New Access Agreement with Scottish Government for ORKAMBI (lumacaftor/ivacaftor) and SYMKEVI (tezacaftor/ivacaftor) Read more
Nucala is the first biologic approved in the US for six to 11-year-old children with severe eosinophilic asthma Read more